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Abstract 
Background: Postoperative sore throat (POST) is a frequent complication of tracheal intubation, 
particularly after surgery in the prone position. We designed this study to validate the 
non-inferiority of magnesium sulphate against dexamethasone for prevention of POST after 
lumbar spinal surgery.  
Methods: One hundred and forty-six patients were randomly allocated to receive either mag-
nesium or dexamethasone. Before anesthetic induction, the magnesium group (n = 73) received 
magnesium sulphate 30 mg/kg followed by 10 mg/kg/h by continuous infusion until the end of 
surgery. The dexamethasone group (n = 73) received dexamethasone 8 mg. The primary endpoint 
was the overall incidence of POST, which was assessed serially over 48 hr postoperatively. The 
predefined margin of non-inferiority for magnesium against dexamethasone was 15%. 
Results: Overall incidences of POST at rest (50.7% versus 49.3% in the magnesium and dexa-
methasone group, respectively, p = 0.869) and swallowing (65.8% versus 61.6% in the magnesium 
and dexamethasone group, respectively, p = 0.606) were not different between the groups. The 
upper limit of the 90% confidence interval, which must be lower than the predefined margin of 
non-inferiority to prove the non-inferiority of magnesium sulphate against dexamethasone, for at 
rest and swallowing were 14.97% (p = 0.0496) and 17.19% (p = 0.0854), respectively. The inci-
dences and severities of POST and hoarseness were also not different between the groups 
throughout the study period. 
Conclusions: Prophylactic magnesium sulphate appears to be non-inferior to dexamethasone for 
the prevention of POST at rest in patients undergoing lumbar spinal surgery in the prone position. 
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Introduction 
Despite being perceived as a minor complica-
tion, postoperative sore throat (POST) is common 
after general anesthesia, occurring in 30% to 65% of 
patients [1,2]. POST contributes to patient dissatisfac-
tion and physical discomfort during the recovery 
phase [3]. POST is attributed to multiple perioperative 
conditions, including local irritation and inflamma-
tion of airway [4], large size of the tracheal tube [5], 
increased duration of surgery [6], movement of tra-
cheal tube and cuff during position change [1], airway 
damage after intubation using rigid stylet [1,7], and 
prone position [8].  
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In lumbar spinal surgery performed in the prone 
position, the incidence and severity of POST is ex-
pected to be high and of great magnitude as it man-
dates the use of wire-reinforced tracheal tube having 
larger outer diameter [9] requiring concomitant use of 
a rigid stylet, and two times of position change while 
being intubated. Thus, efforts to reduce the occur-
rence of POST would be of high priority in this subset 
of patients while evidence is scarce in that regard.  
Numerous pharmacological and non-pharmaco-
logical approaches to prevent or minimize the inci-
dence and severity of POST have been tried with con-
flicting results [4,10,11]. Among them, dexamethasone 
possessing pluripotent action mechanisms has been 
proposed as a relatively well-proven preventive 
measure for POST [2,12], although possible inherent 
complications such as gastric ulcer, infection and hy-
perglycemia limit its widespread use [13].  
Magnesium, an N-methyl-D-aspartate (NMDA) 
receptor antagonist, has potential advantages to play 
a beneficial role in reducing POST through multiple 
mechanisms as well, such as anti-nociceptive and an-
ti-inflammatory effects by inhibiting NMDA recep-
tor-mediated calcium influx [14,15]. Indeed, there are 
evidences to suggest that magnesium can be used for 
reducing the incidence of POST [16,17]. The effect of 
magnesium on POST, however, has rarely been com-
pared with other agents shown to have efficacies in 
that regard, especially in patients undergoing lumbar 
spinal surgery in the prone position who are at in-
creased risk of developing POST.  
Therefore, we designed a non-inferior random-
ized controlled trial to compare the efficacy of mag-
nesium sulphate with dexamethasone for reducing 
POST in patients undergoing lumbar spinal surgery 
in the prone position.  
Methods 
Ethics 
This prospective, randomized, double-blind 
non-inferiority study was conducted at Yonsei Uni-
versity Health System, Seoul, Republic of Korea. Eth-
ical approval for this study (IRB number, 4-2013-0385) 
was provided by the Institutional Review Board of 
Yonsei University Health System, Seoul, Republic of 
Korea. This study was registered at 
www.ClinicalTrials.gov (identified: NCT01923831). 
Informed consents were obtained from all patients 
before enrollment in the study. 
Patient selection 
After obtaining informed written consent from 
all patients, 146 patients requiring general anesthesia 
with tracheal intubation in the prone position for 
elective lumbar spinal surgery, using standard poste-
rior approach, were enrolled. Inclusion criteria were 
20 to 65 year old patients with ASA physical status 
I-II. Exclusion criteria were pre-existing hoarseness or 
sore throat, upper respiratory tract infection, use of 
corticosteroids and calcium channel blockers, allergy 
to magnesium sulphate, Cormack-Lehane grade 3 or 
4, anticipated difficult intubation (a Mallampati score 
III or IV, underlying facial anomaly or a mouth 
opening less than 40mm), more than two attempts at 
intubation, impaired renal function, diabetes mellitus 
or immunocompromized patients. 
Study design 
Patients were randomly allocated into either 
magnesium group (n=73) or dexamethasone group 
(n=73) using a computerized randomization table the 
day before operation by an investigator (J.J), not in-
volved with patient care. For each patient, group as-
signments were kept in sequentially numbered 
opaque, sealed envelopes that were opened by an 
investigator (J.H.K) not involved with patient care. 
In the magnesium group, magnesium sulphate 
30 mg/kg in a total of 100 ml normal saline was given 
for 10 min before the induction of anesthesia, fol-
lowed by continuous infusion of magnesium sulphate 
at 10 mg/kg/h until the end of operation. The chosen 
dose of magnesium sulphate in this study was de-
termined according to a previous study reporting 
efficacy of magnesium for pain control with minimal 
hemodynamic derangement [18]. In the dexame-
thasone group, dexamethasone 8 mg in 100 ml normal 
saline was given for 10 min before the induction of 
anesthesia, followed by continuous infusion of 
equivalent volume of 0.9% saline as in the magnesium 
group. Infusion of magnesium sulphate or normal 
saline was discontinued at skin closure. Study drugs 
were prepared in syringes labelled ‘study drug’ by an 
anesthesiologist, not involved in the study.  
Perioperative management 
Anesthesia was provided by an anesthesiologist 
(J.K.S), blinded to the patients' group allocation. Upon 
arrival at the operating room, standard monitoring 
devices were applied. General anesthesia was in-
duced with propofol 1.5 mg/kg and remifentanil 
0.3-0.5 μg/kg/min, and rocuronium 0.6 mg/kg was 
used for neuromuscular blockade. After loss of all 
four twitches from train-of-four (TOF) stimulation of 
the ulnar nerve, direct laryngoscopy was performed 
using either a Macintosh 3 or 4 laryngoscope blade. 
Wire-reinforced tracheal tubes (MallinckrodtTM 
Lo-Contour cuffed reinforced oral/nasal tracheal 
tube, CovidienTM, Mansfield, OH, USA) of size 8.0 
mm and 7.0 mm internal diameter were inserted for 
male and female patients, respectively, with the aid of 
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a rigid stylet. Application of external laryngeal pres-
sure to aid tracheal intubation, and Cormack and Le-
hane grade were recorded. All intubation procedures 
were performed by an anesthesiologist with an at 
least 2 years of experience, not involved in this study. 
The intra-cuff pressure was monitored with a nonin-
vasive manometer every 15 min and adjusted be-
tween 20-25 cmH2O during operation.  
Anesthesia was maintained with sevoflurane 
1.5-2.5% in an air-oxygen mixture (fraction of inspired 
oxygen = 0.5) and 0.1-0.3 μg/kg/min remifentanil 
infusion. Neuromuscular blockade was monitored 
using TOF stimulation of ulnar nerve. If hypotension 
occurred, reduction in mean arterial pressure below 
20% of preanesthetic value, 200 ml of either Hart-
mann’s solution or normal saline was given. If hypo-
tension persisted for more than 10 minutes, ephedrine 
bolus (4mg, repeated) was administered and record-
ed. If hypotension could not be treated by incremental 
doses of ephedrine, either phenylephrine or nora-
drenaline infusion was started. In all patients, prone 
positioning was done using the Wilson frame with the 
subject's face resting on a foam cushion (Gentle Touch 
Headrest Pillow with Intubation Slot, Mizuho OSI, 
Tokyo, Japan) without rotation of the head. 
At the beginning of the skin closure, an i.v. pa-
tient-controlled analgesia (PCA) device (Accufuser 
plus ®, P2015M, Woo Young Medical Co. Ltd, Korea) 
containing fentanyl 20 μg/kg and ramosetron 0.3 mg 
in normal saline with a total volume of 100 ml was 
connected. This was programmed to deliver 2 mL/h 
as background infusion with a 0.5 ml bolus at 15 min 
lockout period. At the end of the surgery, oxygen 
100% was administered and residual neuromuscular 
blockade was antagonized with pyridostigmine 0.3 
mg/kg and glycopyrrolate 0.004 mg/kg when the 
four responses were detected in TOF stimulation. 
Tracheal tube was removed after patients were fully 
awake. Duration from anesthetic discontinuation to 
response to verbal command and tracheal extubation 
were recorded. The patients were allowed to receive 
tramadol 1mg/kg i.v. if they complained of pain >5 
cm on visual analog scale (VAS) score in recovery 
room and ward. Total number of additional rescue 
analgesics on recovery room and ward for postopera-
tive analgesia was recorded. 
Outcomes 
Assessed primary efficacy variables were the 
overall incidence and severity of POST during the 
study period. The variables were assessed by an an-
esthesiologist (J.W.S), blinded to the group allocation, 
using Harding’s direct questionnaire [19]. The inten-
sity of sore throat was assessed at rest and on swal-
lowing using a 0-10 cm VAS where a score of 0 meant 
no pain and a score of 10 represented the worst pain 
imaginable. 
Assessed secondary efficacy variables were in-
tensity of hoarseness using a 4-graded scale [0 = no 
hoarseness, 1 = mild hoarseness (noticed by the pa-
tient only), 2 = severe hoarseness (noticed at the time 
of the interview by the personnel), 3 = aphonia (ina-
bility to speak)], and the following variables: VAS 
scores of wound pain at rest and upon moving, addi-
tional requirement of rescue analgesics, episodes of 
postoperative nausea and vomiting (PONV). These 
variables were also assessed by an anesthesiologist 
(J.W.S). 
All above mentioned variables were assessed 
serially at 4 periods: 0 to 1, 1 to 6, 6 to 24, and 24 to 48 
hours after operation. Any complication associated 
with magnesium sulphate (e.g., diarrhea, hypoten-
sion) and dexamethasone (e.g., poor glycemic control) 
was also assessed.  
This study was conducted without any changes 
of methods or trial outcomes after trial commence-
ment. An anesthesiologist (J.H.P) blinded to group 
allocation was responsible for collecting data except 
primary and secondary efficacy variables. 
Sample size calculation 
The institutional review board highly recom-
mended not designating a control group in this study 
design, for it would be unethical to neglect the in-
creased risk of POST in the control group. Therefore, 
this study was performed as a non-inferiority trial, 
designating dexamethasone, the commonly used drug 
for preventing POST, as the comparison for the effects 
of magnesium toward POST. As POST had not been 
addressed in this studied patients, we used the high-
est published incidence of POST for sample size cal-
culation. Previous studies have demonstrated that the 
highest incidence of POST with magnesium and 
dexamethasone were 23% and 27%, respectively 
[2,16]. The number of patients required for each group 
was determined on the basis of the non-inferiority 
hypothesis. For non-inferiority of the magnesium 
group versus dexamethasone group, a maximum 
difference of 15 % (margin of non-inferiority) on the 
incidence of POST was considered as acceptable. 
Therefore, we calculated that a study with 65 patients 
per group would have at least 95% power, with 
one-sided type I error of 0.025. Taking into considera-
tion of the 10 percent dropout rate, we decided to 
enroll 73 patients in each group. 
Statistical analysis 
Statistical analyzes were performed using SAS 
version 9.3 (SAS Institute Inc., Cary NC, USA). Cate-
gorical variables were analyzed using chi-square test 
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or Fisher’s exact test and defined as number and per-
centage. Continuous variables were expressed as 
mean ± SD or median [interquartile range] according 
to the normality, using Student’s t-test or 
Mann-Whitney U test, as appropriate. P values of 
<0.05 were considered significant. As secondary 
analysis, we used Bonferroni correction to compare all 
pairs of four evaluation time-points, 0 to 1, 1 to 6, 6 to 
24, 24 to 48 hours after operation, for multiple com-
parisons between the groups and adjusted P value of 
<0.0125 were considered significant. 
Results 
Baseline demographic data 
Among the 180 patients assessed for eligibility, 
146 patients who met the inclusion criteria and agreed 
to participate in this study were enrolled between 
Aug 2013 and Sep 2014 (Figure 1). Of the 146 patients, 
study could be completed in all patients and thus, no 
patient was excluded from statistical analysis. 
The patients' characteristics and operative data 
were not different between the groups (Table 1). Du-
ration from anesthetic discontinuation to response to 
verbal command and tracheal extubation, and the 
amount of remifentanil infused were similar between 
the groups. None of the patients in the magnesium 
group demonstrated signs of prolonged neuromus-
cular blockade. 
 
Table 1. Baseline characteristics of surgical and operative data of 
patients 
Variables Magnesium 
(n = 73) 
Dexame-
thasone 
 (n = 73) 
p 
value 
Age (yrs) 51 ± 12 51 ± 12 0.852  
Female (n) 32 (44%) 31 (43%) 0.999  
Height (cm) 165 ± 10 166 ± 10 0.442  
Weight (kg) 67 ± 12 67 ± 19 0.965  
ASA (I/II) 26/ 47 33/ 40 0.238  
Hypertension (n) 23 (32%) 14 (19%) 0.087  
Cerebrovascular accident (n) 3 (4%) 4 (6%) 0.999  
Smoking (non/past/current) 40/ 14/ 19 52/ 13/ 8  0.115  
Diagnosis (spinal stenosis/disc herni-
ation) 
37/ 36 38/ 35 0.868  
Surgery (posterior fu-
sion/laminectomy) 
30/ 43 36/ 37 0.318  
Duration of tracheal intubation (min)  140 [100-200] 130 [86-187] 0.371  
Duration of surgery (min) 190 [140-243] 170 [138-245] 0.300  
Cormack-Lehane grade (1/2) 49/ 24 58/ 15 0.092  
External compression (n) 23 (32%) 14 (19%) 0.087  
Time to response to verbal command 
(min) 
10 [6-13] 10 [7-12] 0.831  
Time to extubation (min) 11 [9-14] 11 [9-13] 0.562  
Total amount of rocuronium (mg) 39 [35-44] 40 [34-46] 0.925 
Values are number of patients (percentage), mean ± standard deviation or median 
[interquartile range].  
ASA, American Society of Anesthesiologists Physical Status Classification. 
 
 
 
Figure 1. Flow chart describing recruitment, allocation, follow-up and analysis 
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Efficacy data 
Primary outcome 
The incidence and severity of POST are shown in 
Table 2. Overall incidences of POST at rest (50.7% 
versus 49.3% in the magnesium group and dexame-
thasone group, respectively, p = 0.869) and swallow-
ing (65.8% versus 61.6% in the magnesium group and 
dexamethasone group, respectively, p = 0.606) were 
not significantly different between the groups. Re-
spective incidences of POST, which were serially as-
sessed at various predefined time points were also all 
similar between the groups. Overall, the upper limit 
of the 90% confidence interval for overall incidence, 
which must be lower than the predefined margin of 
non-inferiority (15%) to prove the non-inferiority of 
magnesium sulphate against dexamethasone, were 
14.97% (p = 0.0496) and 17.19% (p = 0.0854) at rest and 
swallowing, respectively. The upper limits of the 90% 
confidence interval of the serially assessed time points 
of assessment were all below 15% (all p values <0.05) 
except at 6-24 h on swallowing, which was 18.86% (p 
= 0.13) (Figure 2). The VAS scores for the severity of 
POST were all similar between the groups with me-
dian values ranging from 1 to 2 at all time points of 
assessment. The number of patients who experienced 
POST VAS score of higher than 4 during the study 
period was 11 (15.1%) and 12 (16.4%) in the magne-
sium and dexamethasone group, respectively (p = 
0.820). The number of patients who indicated POST 
VAS score 1 at least once during the study period was 
39 (53.4%) and 38 (52.1%) in the magnesium group 
and dexamethasone group, respectively (p = 0.868). 
 
Table 2. Incidence and severity of postoperative sore throat 
Evaluation time points Magnesium 
(n = 73) 
Dexamethasone 
 (n = 73) 
p value 
Overall incidence    
 sore throat at rest 37 (50.7%) 36 (49.3%) 0.869 
 sore throat on swallowing 48 (68.5%) 45 (61.6%) 0.606 
0-1 hour (incidence/severity*)†   
 sore throat at rest 32 (43.8%) / 1 [1-2] 34 (46.6%) / 2 
[1-3] 
0.739 / 
0.021  
 sore throat on swallowing 43 (58.9%) / 2 [1-2] 43 (58.9%) / 2 
[1-3]  
0.999 / 
0.103  
1-6 hour (incidence/severity*)†   
 sore throat at rest 26 (35.6%) / 1 [1-2] 25 (34.2%) / 2 
[1-2] 
0.999 / 
0.255 
 sore throat on swallowing 36 (49.3%) / 2 [1-2] 35 (47.9%) / 2 
[1-3] 
0.868 / 
0.164  
6-24 hour (incidence/severity*)†   
 sore throat at rest 13 (17.8%) / 1 [1-3] 10 (13.7%) / 2 
[1-3] 
0.496 / 
0.499  
 sore throat on swallowing 22 (30.1%) / 1 [1-3] 17 (23.3%) / 2 
[1-2.5] 
0.350 / 
0.367  
24-48 hour (incidence/severity*)†   
 sore throat at rest 7 (9.6%) / 1 [1-1] 4 (5.5%) / 1 [1-1] 0.347 / 
0.450  
 sore throat on swallowing 12 (16.4%) / 1 [1-2.75] 8 (11.0%) / 1 
[1-1] 
0.336 / 
0.243  
Values are number of patients (percentage) or median [interquartile range]. 
*Severity of postoperative sore throat is expressed as visual analog scale from 0 to 
10. 
†P value was corrected with Bonferroni method for multiple comparisons and 
<0.0125 was considered to be statistically significant. 
 
 
 
 
 
Figure 2. Difference in the incidence of postoperative sore throat. *Against the hypothesis of 15% difference between the magnesium group and dex-
amethasone group. †Overall incidence of postoperative sore throat. CI, confidence interval. 
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Secondary outcomes 
Postoperative hoarseness occurred in more than 
half of patient in both group. The incidence and in-
tensity of hoarseness were not statistically signifi-
cantly different during the study period (Table 3). 
The VAS scores for postoperative pain were 
similar between the groups throughout the study pe-
riod, whereas more patients in the magnesium group 
required additional rescue analgesics at time periods 
of 6 to 24 hours [33 (45.2%) versus 18 (24.7%), p = 
0.009], and 24 to 48 hours [30 (41.1%) versus 9 (12.3%), 
p <0.001)] after operation. Total dose of tramadol for 
postoperative analgesia was significantly higher in 
the magnesium group (118 [22-228] mg) than in the 
dexamethasone group (57 [0-95] mg) (p=0.001). The 
cumulative volumes of consumed opioid-based PCA 
were not different between the groups throughout the 
study period (Table 4). 
 
Table 3. Incidence and severity of hoarseness and the number of 
patients who required vasoactive drugs 
  Magnesium 
(n = 73) 
Dexamethasone 
 (n = 73) 
p value 
Patients with hoarseness*    
Overall incidence 43 (58.9%) 42 (57.5%) 0.867 
 0-1 hour  35 (47.9%) 36 (49.3%) 0.868 
 1-6 hour 36 (49.3%) 30 (41.1%) 0.318 
 6-24 hour 19 (26.0%) 15 (20.5%) 0.433 
 24-48 hour 12 (16.4%) 6 (8.2%) 0.131 
    
Hoarseness severity† (0/1/2/3)*   
 0-1 hour  38/31/4/0 37/35/1/0 0.398 
 1-6 hour 37/33/3/0 43/26/4/0 0.484 
 6-24 hour 54/18/0/1 58/8/5/2 0.014 
 24-48 hour 61/10/0/2 67/5/0/1 0.384 
    
Number of patients who required vasoactive drugs 
 Ephedrine  48 (65.8%) 38 (52.1%) 0.093 
 Phenylephrine  4 (5.5%) 5 (6.8%) 0.731 
 Noradrenaline  11 (15.1%) 8 (11.0%) 0.461 
Values are number of patients (percentage) or median [interquartile range].  
*The adjusted p value <0.0125 was considered significant after Bonferroni correc-
tion. †Hoarseness severity, 0 = no hoarseness, 1 = mild hoarseness (noticed by the 
patient only), 2 = severe hoarseness (noticed at the time of the interview by the 
personnel), 3 = aphonia (inability to speak).  
 
 
Blood glucose level after operation was signifi-
cantly higher in dexamethasone group (136.3 ± 32.92 
mg/dL versus 116.1 ± 21.17 mg/dL, p <0.001) while 
preoperative glucose level was similar between the 
groups. Level of maximal blood magnesium concen-
tration was 1.85 [1.745-2.015] mg/dL in the magne-
sium group and 1.33 [1.290-1.430] mg/dL in the 
dexamethasone group (p <0.001). The number of pa-
tients who experienced at least one hypotensive event 
was 53 (72.6%) and 40 (54.8%) in the magnesium 
group and dexamethasone group, respectively (p = 
0.003). In all hypotensive events, blood pressure could 
be easily restored by predefined measures alone. 
Overall incidence of PONV was 35.6% in the magne-
sium group and 31.5% in the dexamethasone group (p 
= 0.599). Eleven patients were treated with antibiotics 
for postoperative wound infection; 5 patients in the 
magnesium group and 6 patients in the dexame-
thasone group (p = 0.754). Diarrhea was present in 
one patient in the magnesium group at the second 
postoperative day, which was spontaneously resolved 
without any intervention (Table 5). 
 
Table 4. Postoperative analgesic profiles 
  Magnesium  
(n = 73) 
Dexame-
thasone 
 (n = 73) 
p value 
VAS scores of pain (at rest/ at mov-
ing)* 
   
 0-1 hour  4 [2-6]/ 5 
[3-7] 
4 [3-6]/ 5 
[3-7] 
0.731/ 
0.791 
 1-6 hour 3 [2-5]/ 5 
[3-7] 
3 [3-5]/ 5 
[4-7] 
0.534/ 
0.530 
 6-24 hour 3 [2-4]/ 4 
[3-6] 
3 [2-3]/ 4 
[3-5] 
0.056/ 
0.335 
 24-48 hour 2 [2-3]/ 3 
[3-5] 
2 [1-3]/ 3 
[2-4] 
0.398/ 
0.134 
    
Number of patients who required analgesics* 
 Overall 55 (75.3%) 47 (64.4%) 0.149 
 0-1 hour  26 (35.6%) 20 (27.4%) 0.285 
 1-6 hour 30 (41.1%) 27 (37.0%) 0.611 
 6-24 hour 33 (45.2%) 18 (24.7%) 0.009 
 24-48 hour 30 (41.1%) 9 (12.3%) <0.001 
    
Total tramadol dose for pain rescue 
(mg) 
118 [22-228] 57 [0-95] 0.001 
    
Cumulative volume of PCA con-
sumed (mL)* 
   
 0-1 hour  1 [0-2] 1 [0-2] 0.752 
 1-6 hour 15 [13.5-20] 15 [14-20] 0.383 
 6-24 hour 60 [50-62.5] 58 [50-60] 0.652 
 24-48 hour 100 [95-100] 100 [100-100] 0.216 
Values are number of patients (percentage) or median [interquartile range].  
VAS, visual analog scale; PCA, patient-controlled analgesia. 
*The adjusted p value <0.0125 was considered significant after Bonferroni correc-
tion. 
 
Table 5. Complications associated with the studied drugs 
  Magnesium  
(n = 73) 
Dexamethasone 
 (n = 73) 
p 
value 
Preoperative glucose (mg/dL) 98.3 ± 13.89  102.0 ± 14.91 0.122 
Postoperative glucose (mg/dL) 116.1 ± 21.17 136.3 ± 32.92 <0.001 
Maximal magnesium (mg/dL) 1.85 
[1.745-2.015] 
1.33 
[1.290-1.430] 
<0.001 
Perioperative hypotension 53 (72.6%) 40 (54.8%) 0.003 
Vasopressor use 49 (67.1%) 38 (52.1%) 0.064 
Postoperative nausea and vomit-
ing 
26 (35.6%) 23 (31.5%) 0.599 
Postoperative wound infection 5 (6.8%) 6 (8.2%) 0.754 
Diarrhea 1 (1.4%)  0 (0.0%) >0.999 
Values are number of patients (percentage), mean ± standard deviation or median 
[interquartile range]. 
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Discussion 
In this prospective, double-blind, randomized, 
and non-inferiority trial, we could not observe any 
statistically significant differences in the incidence 
and severity of POST between the magnesium and 
dexamethasone group in patients undergoing lumbar 
spinal surgery in the prone position. The majority of 
patients in both groups presented POST VAS scores of 
less than 3. In addition, the incidence and severity of 
hoarseness were also not different between the 
groups. Non-inferiority analysis using the upper limit 
of the 90% confidence interval revealed that magne-
sium sulphate appears to be non-inferior to dexame-
thasone for the prevention of POST at rest in this 
subset of patients. 
Albeit the clinicians have perceived POST as a 
natural consequence of tracheal intubation rather than 
complication [20], it may significantly affect the qual-
ity of life and satisfaction of patients during the re-
covery period [21]. Consequently, increasing efforts 
for preventing or minimizing the occurrence of POST 
during the postoperative recovery period have been 
attempted [1], while no conclusive measures were 
elucidated yet, especially in patients undergoing 
lumbar spinal surgery.  
Since POST is mainly mediated by an inflam-
matory response causing airway mucosal trauma or 
tissue damage [1], and is a sort of postoperative pain 
frequently aggravated with PONV [6], pharmacologic 
agents possessing anti-inflammatory, an-
ti-nociceptive, and anti-emetic effects would be ideal 
for the prevention and treatment of POST. Various 
agents have been examined for POST such as dexa-
methasone [2], inhaled beclomethasone [11], benzy-
damine hydrochloride spray [22], or transdermal ke-
toprofen with controversial results [23]. Among them, 
dexamethasone showed promising results [24], which 
might be attributable to its multidisciplinary mecha-
nisms. Magnesium also has a theoretical potential to 
reduce POST in terms of anti-inflammatory [25] and 
anti-nociceptive effect [16], though the effect on 
PONV was controversial. Recently, magnesium 
showed a beneficial effect on POST at a clinically rel-
evant dose without complications [16]. Therefore, we 
compared the effects of magnesium and dexame-
thasone on POST in patients undergoing lumbar spi-
nal surgery in the prone position, who are at increased 
risk of developing POST, which has not been ad-
dressed heretofore. Since the studied patients were at 
increased risk of developing POST, we designed a 
non-inferiority trial to avoid establishment of place-
bo-control group. 
As our results indicate, the incidence and sever-
ity of POST were all similar between the groups at all 
time points of assessment. Non-inferiority analysis 
revealed that magnesium sulphate was non-inferior to 
dexamethasone for the prevention of POST in terms of 
the overall incidence at rest, whereas it only showed a 
trend towards being non-inferior in terms of the 
overall incidence on swallowing (p = 0.0854). How-
ever, detailed analysis revealed that magnesium sul-
phate was non-inferior to dexamethasone at all seri-
ally assessed time points of measurement except at 
6-24 h on swallowing, which implicates the 
non-inferiority of magnesium sulphate to dexame-
thasone regarding the prevention of POST. 
Of note, the overall incidence of POST during 
study period was more than 60% in both groups de-
spite the use of potentially preventive medications, 
whereas the majority of patients in this study pre-
sented very low VAS scores for POST in comparison 
with previous studies [2,6,12]. The median VAS score 
of 1 for POST implies that the patient did not perceive 
POST until they were interviewed. Nonetheless, pa-
tients were considered as having POST as long as the 
VAS score was ≥1 in the current study. Therefore, the 
high incidence of POST in this study should not dis-
courage the use of both studied drugs as most of the 
patients had a VAS score of less than 3. Indeed, the 
overall incidence of patients with POST VAS score of 
higher than 4 was only 15.1% and 16.4% in the mag-
nesium group and dexamethasone group, respec-
tively (p = 0.820). Thus, these results implicate that 
both magnesium sulphate and dexamethasone could 
effectively mitigate the development of clinically sig-
nificant POST in this high-risk group of patients.  
Notably, patients treated with dexamethasone 
required less rescue analgesics during 6 to 24 hours, 
and 24 to 48 hours after operation with comparable 
cumulative infused volume of PCA and VAS scores 
for pain compared with the patients in the magnesi-
um group. Beneficial effect of dexamethasone to re-
duce postoperative pain and analgesic requirement in 
various surgical patients [26] including lumbar spinal 
surgical patients [27] have been well documented. On 
the contrary, the effect of magnesium sulphate on 
postoperative pain is still controversial [28,29], while 
some studies reported better pain relief with in-
traoperative magnesium sulphate compared to pla-
cebo [15,30]. Direct comparison between the magne-
sium sulphate and dexamethasone against postoper-
ative pain has not been addressed yet, and the result 
of this study demonstrated superior efficacy of dex-
amethasone over magnesium sulphate in reducing 
postoperative pain.  
The PONV is known to increase the susceptibil-
ity of pain [31,32], and is frequently accompanied 
with POST [6]. Among the available anti-emetics, 
dexamethasone has been extensively studied and 
widely used for the reduction of PONV [33]. The ef-
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ficacy of magnesium on antiemetic prophylaxis for 
PONV is not quite satisfactory heretofore [30]. In this 
study, however, both drugs exerted comparable effi-
cacy on the severity as well as the incidence of PONV 
throughout the study period.  
One of the concerns of using dexamethasone is 
the potential for poor glycemic control. In this study, 
postoperative glucose level measured at immediate 
postoperative period was higher in the dexame-
thasone group. The clinical significance of this minor 
increase in blood glucose level in the dexamethasone 
group is beyond the scope of this study to discuss and 
remains to be proven. Considering the results of the 
current trial, magnesium sulphate could be a valuable 
option for the prevention of POST when the use of 
dexamethasone may not be appropriate for its poten-
tial side-effects. 
This study is subject to following limitations. 
Since we excluded patients with expected difficult 
intubation to control confounding variables, general-
ization of this result should be exercised with caution. 
While the dose of magnesium sulphate was deter-
mined based on the estimated safe dose without he-
modynamic consequences, the dose of magnesium 
used in this study might not be an optimal dose for 
POST, which merits further studies in that regard. 
Likewise, same limitation applies to the chosen dose 
of dexamethasone in this study.  
In conclusion, prophylactic magnesium sulphate 
appears to be non-inferior to dexamethasone for pre-
vention of POST at rest in patients undergoing lumbar 
spinal surgery in the prone position. 
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